Industry resources and insights

Sort by year
  • All time
  • 2026
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020 and older
Insider Insights
20.05.2026
Orphan medicines in the EU: Key EU General Pharma ...

EU GPL: A Shift Towards More Selective Incentives for Orphan Drug Manufacturers In March 2026, the ...

Read more
Insider Insights
06.05.2026
Germany’s Draft SHI Reform Bill: Implications fo...

Germany’s draft GKV Contribution Rate Stabilisation Act signals a clearly tighter environment ...

Read more
Articles
06.05.2026
Playing the Long Game: How Early Scientific Advice...

Early HTA scientific advice reduces price and reimbursement risk by informing ev...

Read more
Articles
13.04.2026
Don’t Wait for a JSC: Unlocking Value Through H...

While missing an EU Joint Scientific Consultation (JSC) is suboptimal, the greater strategic concern...

Read more
Articles
30.03.2026
From Evidence to Negotiation: Succeeding Under Ita...

From 1 April 2026, AIFA’s updated HTA guidelines will come into effect, making ...

Read more
Articles
30.03.2026
TrumpRx in Focus: Assessing the Implications for ...

Our previous article explored how TrumpRx might influence drug pricing in the US, the potential ...

Read more
Load more
Browse by topic
Content type
  • All
  • Articles
  • Case Studies
  • Checklist
  • Guide
  • Insider Insights
  • News
  • Poster
  • Publications
  • Webinar
Subscribe
This field is for validation purposes and should be left unchanged.
This field is hidden when viewing the form
Consent

Talk to an expert

Remap Consulting have significant experience working with pharmaceutical and biotech companies in helping them navigate global market access.​

Get in touch